BPC 157: The peptide with big claims and scant evidence STAT Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York